Michael P. Lux
A5058627245- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- BRCA gene mutations in cancer
- Cancer Treatment and Pharmacology
- Economic and Financial Impacts of Cancer
- Breast Lesions and Carcinomas
- Cancer Genomics and Diagnostics
- Health Systems, Economic Evaluations, Quality of Life
- PARP inhibition in cancer therapy
- Medical and Health Sciences Research
- Breast Implant and Reconstruction
- Law and Political Science
- Global Cancer Incidence and Screening
- Cancer Immunotherapy and Biomarkers
- Cancer Risks and Factors
- Clinical practice guidelines implementation
- Ovarian cancer diagnosis and treatment
- Cancer survivorship and care
- Health and Medical Studies
- Corporate Governance and Law
- Digital Radiography and Breast Imaging
- Biosimilars and Bioanalytical Methods
- Public Administration and Political Analysis
- German Literature and Culture Studies
Brüderkrankenhaus St. Josef Paderborn
2019-2025
St. Josef Krankenhaus
2019-2024
St. Josefs Hospital
2024
Olgahospital
2013-2024
Universitätsklinikum Erlangen
2011-2023
Comprehensive Cancer Center Erlangen
2013-2023
St. Vincenz-Krankenhaus Limburg
2020-2023
Paderborn University
2019-2022
Friedrich-Alexander-Universität Erlangen-Nürnberg
2012-2021
Roche (Switzerland)
2021
It is believed widely that chemotherapy-induced cognitive impairment occurs in a subgroup of patients with breast cancer. However, recent reports have provided no evidence chemotherapy affects cognition. In this study, the authors questioned whether compromise cancer attributable to chemotherapy. addition, effects therapy-induced menopause and erythropoiesis-stimulating factor darbepoetin alpha on performance were assessed.A battery neuropsychological tests was used assess 101 before...
The pathological complete response (pCR) after neoadjuvant chemotherapy is a surrogate marker for favorable prognosis in breast cancer patients. Factors capable of predicting pCR, such as the proliferation Ki67, may therefore help improve our understanding drug and its effect on prognosis. This study investigated predictive prognostic value Ki67 patients with invasive receiving treatment cancer. was stained routinely from core biopsies 552 directly fixation embedding process. HER2/neu,...
Introduction MicroRNAs (miRNAs, miRs) are a class of small, non-coding RNA molecules with relevance as regulators gene expression thereby affecting crucial processes in cancer development. MiRNAs offer great potential biomarkers for detection due to their remarkable stability blood and characteristic many different diseases. We investigated whether microarray-based miRNA profiling on whole could discriminate between early stage breast patients healthy controls. Methods performed 48 at...
PURPOSE To compare giredestrant and physician's choice of endocrine monotherapy (PCET) for estrogen receptor–positive, HER2-negative, advanced breast cancer (BC) in the phase II acelERA BC study (ClinicalTrials.gov identifier: NCT04576455 ). METHODS Post-/pre-/perimenopausal women, or men, age 18 years older with measurable disease/evaluable bone lesions, whose disease progressed after 1-2 lines systemic therapy (≤1 targeted, ≤1 chemotherapy regimen, prior fulvestrant allowed) were randomly...
Leitlinienprogramm Onkologie der AWMF, Deutschen Krebsgesellschaft e. V. und Krebshilfe
Triple-negative (TN) breast cancer is an aggressive subtype of associated with a unique set epidemiologic and genetic risk factors. We conducted two-stage genome-wide association study TN (stage 1: 1529 cases, 3399 controls; stage 2: 2148 1309 controls) to identify loci that influence risk. Variants in the 19p13.1 PTHLH showed significant associations (P < 5 × 10−8) 1 2 combined. Results also suggested substantial enrichment significantly variants among single nucleotide polymorphisms (SNPs)...
Complaints of cognitive dysfunction are frequent among cancer patients. Many studies have identified neuropsychological compromise associated with and therapy; however, the was not related to self-reported dysfunction. In this prospective study, authors examined if confounding factors masked an underlying association self-perceived function actual performance. Determinants were investigated.Self-perceived performance assessed before treatment, at end 1 year after baseline in 101 breast...
Increasing effort has been put in the implementation and certification of breast centers order to establish standardized, quality assured health care for cancer patients. The aim this analysis was investigate whether patients treated certified (CBC) have a favorable prognosis as compared outside treatment units.The data 3,940 with invasive nonmetastatic were analyzed regard differences patient tumor characteristics crude overall survival according diagnosis or CBC Middle Franconia, Germany....
Breast and ovarian cancer (BC/OC) predisposition has been attributed to a number of high‐ moderate low‐penetrance susceptibility genes. With the advent next generation sequencing (NGS) simultaneous testing these genes become feasible. In this monocentric study, we report results panel‐based screening 14 BC/OC ( BRCA1, BRCA2, RAD51C, RAD51D, CHEK2, PALB2, ATM, NBN, CDH1, TP53, MLH1, MSH2, MSH6 PMS2 ) in group 581 consecutive individuals from German population with BC and/or OC fulfilling...
Progress has been made in the treatment of metastatic breast cancer recent decades, but very few therapies use patient or tumor-specific characteristics to tailor individualized treatment. More than ten years after publication reference human genome sequence, analysis methods have improved enormously, fostering hope that biomarkers can be used individualize and offer precise based on tumor characteristics. Biomarkers at every level system (genetics, epigenetics, gene expression, micro-RNA,...
The aim of this official guideline coordinated and published by the German Society for Gynecology Obstetrics (DGGG) Cancer (DKG) was to optimize screening, diagnosis, therapy follow-up care breast cancer.
•Final safety and efficacy results from PERUSE with ∼6 years' median follow-up are consistent CLEOPATRA results.•Results provide reassurance that paclitaxel is a valid alternative to docetaxel first-line pertuzumab trastuzumab.•In exploratory analyses, presence of both visceral disease prior trastuzumab identified subgroup worse PFS. BackgroundThe phase III CLinical Evaluation Of Pertuzumab And TRAstuzumab (CLEOPATRA) trial established the combination pertuzumab, as standard therapy for...
Among patients with metastatic breast cancer (mBC), the frequency of germline mutations in susceptibility genes and clinical relevance these are unclear. In this study, a prospective cohort mBC was used to determine mutation rates for (BC) predisposition genes, evaluate characteristics mutations, assess influence on patient outcome.
The efficacy of sacral nerve stimulation (SNS) to treat faecal incontinence has been demonstrated in the short- and mid-term. We analysed SNS outcome first patients with a permanent neurostimulator whom follow-up ranges up 14 years.Of 12 who underwent from 1994 1999, 9 were eligible for long-term analysis (defined as minimum 7 years). In 3 device had be removed because pain or neurological disease. Functional was monitored prospectively by standardized questionnaire. For efficacy, recorded...